197 related articles for article (PubMed ID: 28258399)
21. On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?
Vallejo-Torres L; García-Lorenzo B; Castilla I; Valcárcel-Nazco C; García-Pérez L; Linertová R; Polentinos-Castro E; Serrano-Aguilar P
Value Health; 2016; 19(5):558-66. PubMed ID: 27565273
[TBL] [Abstract][Full Text] [Related]
22. Societal value of stem cell therapy in stroke--a modeling study.
Svensson J; Ghatnekar O; Lindgren A; Lindvall O; Norrving B; Persson U; Kokaia Z
Cerebrovasc Dis; 2012; 33(6):532-9. PubMed ID: 22571941
[TBL] [Abstract][Full Text] [Related]
23. A Tale of Two Thresholds: A Framework for Prioritization within the Cancer Drugs Fund.
Leigh S; Granby P
Value Health; 2016; 19(5):567-76. PubMed ID: 27565274
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Laparoscopic Hysterectomy With Morcellation Compared With Abdominal Hysterectomy for Presumed Myomas.
Rutstein SE; Siedhoff MT; Geller EJ; Doll KM; Wu JM; Clarke-Pearson DL; Wheeler SB
J Minim Invasive Gynecol; 2016 Feb; 23(2):223-33. PubMed ID: 26475764
[TBL] [Abstract][Full Text] [Related]
25. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
[TBL] [Abstract][Full Text] [Related]
26. Exploring a new method for deriving the monetary value of a QALY.
Tilling C; Krol M; Attema AE; Tsuchiya A; Brazier J; van Exel J; Brouwer W
Eur J Health Econ; 2016 Sep; 17(7):801-9. PubMed ID: 26289341
[TBL] [Abstract][Full Text] [Related]
27. The 3-Year Cost-Effectiveness of a Nurse-Based Case Management versus Usual Care for Elderly Patients with Myocardial Infarction: Results from the KORINNA Follow-Up Study.
Seidl H; Hunger M; Meisinger C; Kirchberger I; Kuch B; Leidl R; Holle R
Value Health; 2017 Mar; 20(3):441-450. PubMed ID: 28292489
[TBL] [Abstract][Full Text] [Related]
28. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation.
Simpson EL; Duenas A; Holmes MW; Papaioannou D; Chilcott J
Health Technol Assess; 2009 Mar; 13(17):iii, ix-x, 1-154. PubMed ID: 19331797
[TBL] [Abstract][Full Text] [Related]
29. Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment.
van de Wetering L; van Exel J; Bobinac A; Brouwer WB
Pharmacoeconomics; 2015 Dec; 33(12):1289-300. PubMed ID: 26232199
[TBL] [Abstract][Full Text] [Related]
30. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
31. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
Beresniak A; Dupont D
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
[TBL] [Abstract][Full Text] [Related]
32. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
[TBL] [Abstract][Full Text] [Related]
33. Which is more valuable, longer survival or better quality of life? Israeli oncologists' and family physicians' attitudes toward the relative value of new cancer and congestive heart failure interventions.
Greenberg D; Hammerman A; Vinker S; Shani A; Yermiahu Y; Neumann PJ
Value Health; 2013; 16(5):842-7. PubMed ID: 23947979
[TBL] [Abstract][Full Text] [Related]
34. The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature.
Ryen L; Svensson M
Health Econ; 2015 Oct; 24(10):1289-1301. PubMed ID: 25070495
[TBL] [Abstract][Full Text] [Related]
35. Analyzing cost-effectiveness of ulnar and median nerve transfers to regain forearm flexion.
Wali AR; Park CC; Brown JM; Mandeville R
Neurosurg Focus; 2017 Mar; 42(3):E11. PubMed ID: 28245686
[TBL] [Abstract][Full Text] [Related]
36. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation.
King JT; Tsevat J; Lave JR; Roberts MS
Med Decis Making; 2005; 25(6):667-77. PubMed ID: 16282217
[TBL] [Abstract][Full Text] [Related]
37. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
[TBL] [Abstract][Full Text] [Related]
38. Health technology assessment with risk aversion in health.
Lakdawalla DN; Phelps CE
J Health Econ; 2020 Jul; 72():102346. PubMed ID: 32592923
[TBL] [Abstract][Full Text] [Related]
39. Determining Value in Health Technology Assessment: Stay the Course or Tack Away?
Caro JJ; Brazier JE; Karnon J; Kolominsky-Rabas P; McGuire AJ; Nord E; Schlander M
Pharmacoeconomics; 2019 Mar; 37(3):293-299. PubMed ID: 30414074
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
